Loading...
•
Dec 31, 2022
PMV Pharma Q4 2022 Earnings Report
PMV Pharma reported financial results for full year 2022 and provided a corporate update.
Key Takeaways
PMV Pharmaceuticals reported cash, cash equivalents, and marketable securities of $243.5 million as of December 31, 2022. Net loss for the year ended December 31, 2022, was $73.3 million. The company is focusing on clinical development of PC14586 and the pipeline program R282W.
Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586.
Enrolled first patient in combination arm of the PYNNACLE study with PC14586 and KEYTRUDA.
Cash, cash equivalents, and marketable securities totaled $243.5 million as of December 31, 2022.
Preliminary results from the ongoing Phase 1/2 PYNNACLE study of PC14586 were featured at ASCO 2022 Annual Meeting.
PMV Pharma
PMV Pharma
Forward Guidance
PMV expects to provide next clinical update in 2H 2023.